- BioCentriq has appointed Syed T. Husain as its new Chief Executive Officer (CEO).
- Husain brings over 20 years of experience in CDMO and cell therapy development to BioCentriq’s next growth phase.
BioCentriq has appointed Syed T. Husain as its new Chief Executive Officer (CEO) and a member of the Board of Directors, marking a new chapter in the company’s growth in the cell and gene therapy (CGT) sector. Husain, a veteran with over 20 years of experience in contract development and manufacturing organization (CDMO) services, brings extensive knowledge of the CGT value chain and the drug commercialization lifecycle.
The appointment comes as BioCentriq aims to strengthen its position in the cell and gene therapy market. Husain’s strategic leadership and proven track record will support the company’s transition from early-stage clinical development to commercial manufacturing. As James Park, Chairman of the Board at BioCentriq, commented, “Syed’s extensive experience in CDMO business expansion will be pivotal in ensuring BioCentriq’s leadership in manufacturing innovation and in spearheading the clinical to commercial manufacturing of cutting-edge cell therapies.”
Prior to joining BioCentriq, Husain was Chief Commercial Officer at Resilience, where he played a key role in building an industry-leading commercial organisation and securing multi-billion-dollar contracts. His previous leadership roles at Emergent BioSolutions, Alcami Corporation, and Lonza have further solidified his expertise in the sector.
Speaking on his new role, Husain said, “As BioCentriq moves into its next phase of growth, we’re committed to strengthening our capabilities even further. Our goal is to drive the approval of new CGT modalities by offering a complete end-to-end solution—from clinical to commercial manufacturing—ensuring that life-changing therapies reach the patients who need them most.”
Overview of outsourcing trends 
